or Try an Advanced Search...

    Non Small Cell Lung Cancer Stocks List

    Symbol Grade Name % Change
    XOMA B XOMA Corporation -1.47
    VCNX F Vaccinex, Inc. 3.00
    PYXS D Pyxis Oncology, Inc. 0.23
    PPBT F Purple Biotech Ltd. 3.42
    PBYI D Puma Biotechnology Inc 0.20
    OPK B OPKO Health Inc. 2.36
    NVCR F NovoCure Limited 11.38
    NXTC D NextCure, Inc. 8.76
    LYEL B Lyell Immunopharma, Inc. 3.00
    LCTX F Lineage Cell Therapeutics, Inc. -7.08
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Instruments & Supplies
    Related Stock Lists: Cancer Small Cell Lung Cancer Biotechnology Medicine Clinical Medicine Solid Tumors Treatment Of Non Small Cell Lung Cancer Biology Cancer Treatment Immune System Immunology Immunotherapy Osteoarthritis Pancreatic Cancer Tumor Antibodies Antibody Antineoplastic Drugs Clinical Development Degenerative Disease

    Related ETFs - A few ETFs which own one or more of the above listed Non Small Cell Lung Cancer stocks.

    Symbol Grade Name Weight
    GERM C ETFMG Treatments Testing and Advancements ETF 2.44
    CNCR C Loncar Cancer Immunotherapy ETF 1.46
    XHS C SPDR S&P Health Care Services ETF 1.36
    XHE B SPDR S&P Health Care Equipment 1.25
    HTEC D Robo Global Healthcare Technology and Innovation ETF 1.22
    View all Non Small Cell Lung Cancer ETFs...
    Compare ETFs
    Compare GERM to XHE Compare XHS to HTEC Compare XHS to XHE

        Non Small Cell Lung Cancer Stocks Recent News

        Date Stock Title
        May 3 PBYI Puma Biotechnology, Inc. (PBYI) Q1 2024 Earnings Call Transcript
        May 2 PBYI Puma Biotechnology, Inc. 2024 Q1 - Results - Earnings Call Presentation
        May 2 PBYI Puma Biotechnology Inc (PBYI) Reports Q1 Financial Results, Misses Analyst Revenue and EPS Forecasts
        May 2 NXTC NextCure GAAP EPS of -$0.61 misses by $0.15
        May 2 PBYI Puma Biotechnology Non-GAAP EPS of -$0.05 beats by $0.10, revenue of $43.8M misses by $5.25M
        May 2 NXTC NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
        May 2 PBYI Puma Biotechnology Reports First Quarter Financial Results
        May 2 NVCR NovoCure Limited (NVCR) Q1 2024 Earnings Call Transcript
        May 2 NVCR NovoCure Limited 2024 Q1 - Results - Earnings Call Presentation
        May 2 NVCR NovoCure Ltd (NVCR) Q1 2024 Earnings: Revenue Surpasses Estimates, Narrower Net Loss Reported
        May 2 NVCR NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
        May 2 NVCR Novocure secures new $400M multi-tranche debt financing, shares up
        May 2 NVCR NovoCure GAAP EPS of -$0.36 beats by $0.06, revenue of $138.5M beats by $7.05M
        May 2 NVCR Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
        May 2 NVCR Novocure Reports First Quarter 2024 Financial Results
        May 1 PBYI Puma Biotechnology Q1 2024 Earnings Preview
        May 1 NVCR NovoCure Q1 2024 Earnings Preview
        Apr 30 LCTX Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
        Apr 30 XOMA XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
        Apr 29 LCTX Lineage Cell Therapeutics board chairman passes away
        Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Instruments & Supplies
        Related Stock Lists: Cancer Small Cell Lung Cancer Biotechnology Medicine Clinical Medicine Solid Tumors Treatment Of Non Small Cell Lung Cancer Biology Cancer Treatment Immune System Immunology Immunotherapy Osteoarthritis Pancreatic Cancer Tumor Antibodies Antibody Antineoplastic Drugs Clinical Development Degenerative Disease
        Non Small Cell Lung Cancer

        Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all cases. It is a type of cancer that begins in the cells that line the airways of the lungs. NSCLC is divided into three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Symptoms of NSCLC include a persistent cough, chest pain, shortness of breath, and coughing up blood. Treatment options for NSCLC include surgery, chemotherapy, radiation therapy, and targeted therapy.

        Browse All Tags